Lack of complete response pretransplant is not associated with inferior overall survival for stage 4a metastatic retinoblastoma. Issue 1 (8th August 2022)

• Record Type: Journal Article
• Authors: Farouk Sait, Sameer; Bernot, Mauricio Rendon; Klein, Elizabeth; Abramson, David H.; Francis, Jasmine H.; Gilheeney, Stephen; Karajannis, Matthias A.; Spitzer, Barbara; Wolden, Suzanne; Dunkel, Ira J.; Kernan, Nancy A.
• Is Part Of: Pediatric blood & cancer. Volume 70:Issue 1(2023)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2022-08-08
• Subjects: metastatic -- radiation therapy -- retinoblastoma -- transplant; Tumors in children -- Periodicals; Blood -- Diseases -- Periodicals; Cancer in children -- Periodicals; 618.92
• DOI: 10.1002/pbc.29921
• Languages: English
• ISSNs: 1545-5009

Abstract

Abstract: Background: Stage 4a metastatic retinoblastoma (RB) is curable with intensive multimodality therapy including myeloablative chemotherapy with autologous stem cell transplant (HDC‐ASCT) and involved field radiation therapy (IFRT). To our knowledge, no data exist on the impact of (a) pre‐ASCT disease status, and (b) IFRT to sites of metastatic disease post ASCT on survival. Procedure: We retrospectively reviewed patients with stage 4a metastatic RB who underwent induction chemotherapy followed by HDC‐ASCT, with or without IFRT, to residual tumor sites at Memorial Sloan Kettering Cancer Center (MSKCC) ( n = 24). Results: The degree of postinduction response prior to ASCT did not affect outcome, with 5‐year overall survival (OS) of 68% and 86% in patients who achieved complete response (CR) and very good partial response (VGPR)/partial response (PR) prior to ASCT, respectively. IFRT administered post ASCT in patients with possible residual bony metastatic disease increases the likelihood of developing osteosarcoma in the radiation field. Conclusion: OS for patients with stage 4a metastatic RB treated with ASCT with VGPR or PR to pretransplant chemotherapy was not significantly different from patients with CR. In addition, IFRT does not seem to be required for bony disease control and increased the likelihood of developing osteosarcoma.